Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Drescher

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2010
In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's diseaseR Scott Bitner, William H Bunnelle, Michael W Decker, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2005
Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugsAndreas Kling, Udo E W Lange, Helmut Mack, et al.
The EMBO Journal|March 17, 1997
Shared and distinct functions of RAGS and ELF-1 in guiding retinal axonsB Monschau, C Kremoser, K Ohta, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 8, 2011
Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognitionEric G Mohler, Kaitlin E Browman, Victoria A Roderwald, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 21, 2012
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonistTimothy A Esbenshade, Kaitlin E Browman, Thomas R Miller, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
CNS Neuroscience & Therapeutics|May 17, 2008
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing propertiesKarin R Tietje, David J Anderson, R Scott Bitner, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2010
In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's diseaseR Scott Bitner, William H Bunnelle, Michael W Decker, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2005
Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugsAndreas Kling, Udo E W Lange, Helmut Mack, et al.
The EMBO Journal|March 17, 1997
Shared and distinct functions of RAGS and ELF-1 in guiding retinal axonsB Monschau, C Kremoser, K Ohta, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 8, 2011
Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognitionEric G Mohler, Kaitlin E Browman, Victoria A Roderwald, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 21, 2012
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonistTimothy A Esbenshade, Kaitlin E Browman, Thomas R Miller, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
CNS Neuroscience & Therapeutics|May 17, 2008
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing propertiesKarin R Tietje, David J Anderson, R Scott Bitner, et al.
Pageof 6